癌性胸水患者血清和胸水中水溶性细胞角蛋白19片段、癌胚抗原和神经元特异性烯醇化酶检测

Detection of CEA,Cyfra21-1,and NSE in serum and pleural fluid cancerous pleural effusion patients

目的:探讨血清和胸水中的水溶性细胞角蛋白19片段(Cyfra21-1)、癌胚抗原(CEA)和神经元特异性烯醇化酶(NSE)对鉴别癌性胸水和非癌性胸水的诊断价值。方法:采用电化学发光免疫法测定36例癌性胸水和20例非癌性胸水患者胸水和血清中Cyfra21-1、CEA和NSE水平。结果:癌性胸水患者血清和胸水Cyfra21-1、CEA和NSE水平均高于非癌性胸水患者(P均<0.05)。对癌性胸水鉴别比较中,胸水中Cyfra21-1、CEA和NSE的敏感性分别为61.1%、50.0%和13.8%,而血清中Cyfra21-1、CEA和NSE分别为52.7%、36.1%和25.0%。结论:联合测定血清和胸水中的Cyfra21-1和CEA,并辅助细胞学检查,能提高癌性胸水诊断的敏感性。

Aim：To investigate the diagnostic potential of serum and pleural fluid determinations of Cyfra21-1, CEA, and NSE. Methods：Cyfra21-1, CEA, and NSE were quantified by using elcctrochemilumineseenee immunoassay kit in serum and pleural fluid samples of 36 patients with malignant pleural effusions and 20 with benign ones. Results ： Levels of Cyfra21-1, CEA, and NSE in serum and pleural fluid of patients with malignant pleural effusions were significantly higher than those of patients with benign ones（ P 〈0.05 ）. The sensitivity of pleural Cyfra21-1, CEA, and NSE determination in diagnosis of malignant effusions was 61. 1% , 50.0% , and 13.8% , respectively, and those of serum level was 52.7% , 36.1% , and 25.0% , respectively. Conclusion ： Determination of serum and pleural level of Cyfra21-1 and CEA together with＇cytological examination might be helpful to reveal malignant origin of a pleural effusion.